Plain-English translation of NCT06613360 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is an early-stage study of , a new medication given by injection under the skin that works by targeting immune cells involved in lupus. Researchers are testing whether this treatment can help people with moderate to severe lupus who haven't responded well to other available medications. The study will enroll about 24 patients and test different doses to find what works best and is safe.
Many people with lupus don't get enough relief from current treatments, and their disease continues to cause damage despite trying multiple medications. This study exists to see if a new approach that targets a specific type of immune cell might help patients whose lupus hasn't improved with standard care.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would receive injections of the medication under your skin as part of the study, with doses increasing gradually in the first part to ensure safety. Throughout the study, you would have regular visits for blood tests and check-ins to monitor how you're responding and watch for any side effects. The study has two parts: the first determines the right dose, and the second part evaluates the treatment further in patients who tolerated it well.
AI-generated summary from trial data Β· Jun 6, 2026 Β· Not medical advice
United States